Noteworthy news from medtech start-ups. This month we profile Auxogyn, which is developing imaging tools for improving success rates for in vitro fertilization, and Urovalve, which has developed patient-activated bladder management technology.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.